-Led research strategy to discover and develop small molecule inhibitors of synthetic lethality targets fortreatment of biomarker-selected cancer patients-Oversaw pre-clinical discovery and development of clinical molecules telaglenastat (glutaminaseinhibitor) and CB-1158 (arginase inhibitor) and IND candidates CB-708 (CD73 inhibitor) and CB-668 (IL4I1inhibitor) from early discovery to clinical development-Messaged drug rationale to investors, analysts, physicians and external scientists-Supervised biology, pharmacology, DMPK and clinical biomarker departments-Presided over key hires, budgets and corporate policies

-Co-founded, capitalized and operationalized Cleave Biosciences-Built biology team, implemented assays to triage p97 small molecule inhibitors, devised and managed triage cascade to select proof-of-concept molecules

-Early and key member of research and development team for proteasome inhibitor carfilzomib for treating multiple myeloma-Invented, developed and implemented pharmacodynamic and biomarker assays to monitor proteasome activity into clinical trial studies

Performed mechanistic studies on ubiquitin ligase small molecule inhibitors as potential cancer therapeutics

Pioneered assays to prove SNAREs are core machinery proteins responsible for cellular membrane fusion (Lab of nobel laureate James Rothman)